Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evobrutinib dose-ranging phase II study in systemic lupus erythematosus
2016-002950-19Phase 2Terminated
- Sponsor
- Merck KGaA
- Start
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in systemic lupus erythematosus (SLE) comparing Evobrutinib dose-ranging arms with Placebo arm (2 arms). Primary endpoint: Number of subjects with SRI-4 response at Week 52. Started Mar 2017; status: terminated.
02
Drugs
evobrutinib
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2016-002950-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002950-19.